ArticlePloS one2014
Functional heterologous protein expression by genetically engineered probiotic yeast Saccharomyces boulardii.
Article in PloS one, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
26 citing papers in PubMed, 54 citations in OpenAlex.
- Design and immunogenicity of a recombinant Saccharomyces boulardii secreting the P2-VP8 subunit rotavirus vaccine.Scientific reports · 2026Article
- Application ofFoods (Basel, Switzerland) · 2025Review
- A functional surface display system iniScience · 2025Article
- Enabling technologies for in situ biomanufacturing using probiotic yeast.Advanced drug delivery reviews · 2025Review
- Development of a Dihydrofolate Reductase Selection System forInternational journal of molecular sciences · 2025Article
- Engineering Saccharomyces cerevisiae for medical applications.Microbial cell factories · 2025Review
- Novel Insights in the Application of Probiotic YeastFoods (Basel, Switzerland) · 2024Review
- Probiotic Yeasts: A Developing Reality?Journal of fungi (Basel, Switzerland) · 2024Review
- Targeted delivery of the probiotic Saccharomyces boulardii to the extracellular matrix enhances gut residence time and recovery in murine colitis.Nature communications · 2024Article
- Evaluation of the impact of polypeptide-p on diabetic rats upon its cloning, expression, and secretion in Saccharomyces boulardii.Archives of microbiology · 2023Article
- Yeast oral vaccines against infectious diseases.Frontiers in microbiology · 2023Review
- Biocontainment strategies forFrontiers in bioengineering and biotechnology · 2023Article
- Standardization and Key Aspects of the Development of Whole Yeast Cell Vaccines.Pharmaceutics · 2022Review
- Easy efficient HDR-based targeted knock-in inBioengineered · 2022Article
- Effects of broad-spectrum antibiotics on the colonisation of probiotic yeast Saccharomyces boulardii in the murine gastrointestinal tract.Scientific reports · 2022Article
- Self-tunable engineered yeast probiotics for the treatment of inflammatory bowel disease.Nature medicine · 2021Article
- Heterologous Expression of the Leuconostoc Bacteriocin Leucocin C in Probiotic Yeast Saccharomyces boulardii.Probiotics and antimicrobial proteins · 2021Article
- Development of a Potential Yeast-Based Vaccine Platform forFrontiers in immunology · 2021Article
- A probiotic yeast-based immunotherapy againstScience translational medicine · 2020Article
- Immunomodulation of carcinogens-induced steroids-dependent human diseases.Saudi journal of biological sciences · 2019Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 2 institutions in 2 countries.
Funding
Abstract
Recent studies have suggested the potential of probiotic organisms to be adapted for the synthesis and delivery of oral therapeutics. The probiotic yeast Saccharomyces boulardii would be especially well suited for this purpose due to its ability, in contrast to probiotic prokaryotes, to perform eukaryotic post translational modifications. This probiotic yeast thus has the potential to express a broad array of therapeutic proteins. Currently, however, use of wild type (WT) S. boulardii relies on antibiotic resistance for the selection of transformed yeast. Here we report the creation of auxotrophic mutant strains of S. boulardii that can be selected without antibiotics and demonstrate that these yeast can express functional recombinant protein even when recovered from gastrointestinal immune tissues in mice. A UV mutagenesis approach was employed to generate three uracil auxotrophic S. boulardii mutants that show a low rate of reversion to wild type growth. These mutants can express recombinant protein and are resistant in vitro to low pH, bile acid salts, and anaerobic conditions. Critically, oral gavage experiments using C57BL/6 mice demonstrate that mutant S. boulardii survive and are taken up into gastrointestinal immune tissues on a similar level as WT S. boulardii. Mutant yeast recovered from gastrointestinal immune tissues furthermore retain expression of functional recombinant protein. These data show that auxotrophic mutant S. boulardii can safely express recombinant protein without antibiotic selection and can deliver recombinant protein to gastrointestinal immune tissues. These auxotrophic mutants of S. boulardii pave the way for future experiments to test the ability of S. boulardii to deliver therapeutics and mediate protection against gastrointestinal disorders.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.